Publikationen, an denen er mitarbeitet Patricia P. Rada Llano (22)

2024

  1. GDF15 activates AMPK and inhibits gluconeogenesis and fibrosis in the liver by attenuating the TGF-β1/SMAD3 pathway

    Metabolism: Clinical and Experimental, Vol. 152

  2. Inhibition of ALK3-mediated signalling pathway protects against acetaminophen-induced liver injury

    Redox Biology, Vol. 71

2023

  1. Elafibranor upregulates the EMT-inducer S100A4 via PPARβ/δ

    Biomedicine and Pharmacotherapy, Vol. 167

  2. Hypothalamic JNK1-hepatic fatty acid synthase axis mediates a metabolic rewiring that prevents hepatic steatosis in male mice treated with olanzapine via intraperitoneal: Additional effects of PTP1B inhibition

    Redox Biology, Vol. 63

  3. Protective effects of the succinate/SUCNR1 axis on damaged hepatocytes in NAFLD

    Metabolism: Clinical and Experimental, Vol. 145

  4. Soluble epoxide hydrolase-targeting PROTAC activates AMPK and inhibits endoplasmic reticulum stress

    Biomedicine and Pharmacotherapy, Vol. 168

2022

  1. Effects of a Mealworm (Tenebrio molitor) Extract on Metabolic Syndrome-Related Pathologies: In Vitro Insulin Sensitivity, Inflammatory Response, Hypolipidemic Activity and Oxidative Stress

    Insects, Vol. 13, Núm. 10

  2. Enhanced Wild-Type MET Receptor Levels in Mouse Hepatocytes Attenuates Insulin-Mediated Signaling

    Cells, Vol. 11, Núm. 5

  3. Modulation of hypothalamic AMPK phosphorylation by olanzapine controls energy balance and body weight

    Metabolism: Clinical and Experimental, Vol. 137

  4. Ptpn1 deletion protects oval cells against lipoapoptosis by favoring lipid droplet formation and dynamics

    Cell Death and Differentiation, Vol. 29, Núm. 12, pp. 2362-2380

2020

  1. Aripiprazole cytotoxicity coincides with activation of the unfolded protein response in human hepatic cells

    Journal of Pharmacology and Experimental Therapeutics, Vol. 374, Núm. 3, pp. 452-461

  2. Erratum: Aripiprazole Cytotoxicity Coincides with Activation of the Unfolded Protein Response in Human Hepatic Cells (Journal of Pharmacology and Experimental Therapeutics (2020) 374 (452-461) DOI: 10.1124/jpet.119.264481)

    Journal of Pharmacology and Experimental Therapeutics

  3. Insights Into Extracellular Vesicles as Biomarker of NAFLD Pathogenesis

    Frontiers in Medicine, Vol. 7

  4. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?

    Cell Death and Disease, Vol. 11, Núm. 9

2019

  1. Differential effects of metformin glycinate and hydrochloride in glucose production, AMPK phosphorylation and insulin sensitivity in hepatocytes from non-diabetic and diabetic mice

    Food and Chemical Toxicology, Vol. 123, pp. 470-480

  2. Insulin receptor substrate 2 (IRS2) deficiency delays liver fibrosis associated with cholestatic injury

    DMM Disease Models and Mechanisms, Vol. 12, Núm. 7

  3. Protein tyrosine phosphatase 1b deficiency protects against hepatic fibrosis by modulating nadph oxidases

    Redox Biology, Vol. 26

2018

  1. Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis

    Molecular Metabolism, Vol. 7, pp. 132-146

  2. Protection against gamma-radiation injury by protein tyrosine phosphatase 1B

    Redox Biology, Vol. 17, pp. 213-223

  3. SIRT1 Controls Acetaminophen Hepatotoxicity by Modulating Inflammation and Oxidative Stress

    Antioxidants and Redox Signaling, Vol. 28, Núm. 13, pp. 1187-1208